louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06201169: PEEK Bar Versus Titanium Bar Fabricated by CAD-CAM in Mandibular Hybrid Prostheses: A Comparative Study
Official title: Comparative Study of PEEK Bar Versus Titanium Bar Fabricated by CAD-CAM in Mandibular Hybrid Prostheses
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Edentulous Jaw
Keywords: Hybrid prosthesis, Polyether-ether-ketone,
Lead sponsor: Tanta University
Sponsor class: OTHER
Collaborators: name: Tanta University
First posted: 2024-01-11
Enrollment: 14
Sex: ALL
Minimum age (years): 40
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: completely edentulous mandibular arch opposing natural dentition were selected
Primary purpose: SUPPORTIVE_CARE

Brief summary: CAD/CAM-fabricated PEEK bar exhibited greater dimensional deviation in comparison to its titanium counterpart. Nevertheless, patients with PEEK bars reported higher satisfaction levels and lower marginal bone loss when compared to those with titanium bars.

Detailed description: Fourteen patients with completely edentulous mandibular arch opposing natural dentition were selected and divided into two groups, seven patients in each. All patients received implant-supported hybrid prostheses with a bar fabricated by CAD/CAM milling technique. In group I (control), bar was fabricated from titanium, while in group ӀӀ, the bar was fabricated from PEEK. The evaluation of the study was done at 6 and 12 follow-up periods according to the following: 1- Experimentally by Geomagic (Geomagic, Japan) to detect any dimensional deviation of PEEK bars compared to titanium bars. 2-Clinically by questionnaire to evaluate the patient satisfaction. 3- Radiographically (digital periapical) to measure marginal bone loss around the implants.

Eligibility criteria: Inclusion Criteria:

* Completely edentulous mandibular arch for at least six months have almost of the natural teeth in the maxillary arch with a ranged of age from 40- 60 years old.

and normal class Ӏ maxilla-mandibular relationship with a minimum 12-15 mm inter-arch space

Exclusion Criteria:

* All patient had systemic disorders that may influence soft or hard tissue healing were excluded as:

  * History of radiation therapy in the head and neck region.
  * Active infection or inflammation or flabby tissue in the mandibular arch
  * Bone diseases as osteoporosis.
  * Clenching or bruxism, temporomandibular joint troubles
  * Neurological or psychiatric handicap conditions that could interfere with good oral hygiene.
  * Heavy smoking and drug abusing

Primary outcomes:
measure: Radiographically (digital periapical)
timeFrame: six and twelve months
Secondary outcomes:
Other outcomes:
Locations:
city: Al Gharbī Bahjūrah
country: Egypt
facility: Faculty of dentistry tanta university
state: Tanta
city: Al Gharbī Bahjūrah
country: Egypt
facility: Tanta University
state: Tanta
Study officials:
affiliation: Tanta University
name: Research Ethics committee
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04596969: The Effect of Soluble Fiber Dextrin on Subjective and Physiological Markers of Appetite
Official title: The Effect of Soluble Fiber Dextrin on Subjective and Physiological Markers of Appetite: a Randomized Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Appetitive Behavior
Lead sponsor: Iowa State University
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 50
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Intervention model description: Human subjects
Primary purpose: BASIC_SCIENCE

Brief summary: This study examines the effect of soluble fiber dextrin on food intake, appetite, and physiological markers of appetite. Adults aged 18-45 years with a BMI were recruited for this study. Participants were given two doses of SFD in the morning and appetite, food intake and physiological markers of appetite were measured over 10 years.

Detailed description: Overweight and obesity are leading health problems. The study investigates the effect of a food ingredient from two different sources at two different doses on food intake and appetite markers over a 10 hour period. All participants reported to the laboratory first thing in the morning and remained in the laboratory until after their evening meal. A fixed breakfast was served but the participants were free to eat as much as they liked at lunch and dinner. Blood was taken at regular intervals during the day and assayed for glucose and several hormones related to appetite. Subjective measures of appetite were also collected over the 10 hour test session.

Eligibility criteria: Inclusion Criteria:

BMI 19.9 - 29.9 Aged 18-45 Find the study foods to be palatable

Exclusion Criteria:

Weight change \> 3kg in the past three months Do not regularly consume snacks Presence or history of GI disorders Restrained eater Used medication that influences appetite

Primary outcomes:
measure: Food intake
timeFrame: 10 hours
Secondary outcomes:
measure: Appetite
timeFrame: 10 hours
measure: CCK
timeFrame: 10 hours
measure: GLP-1
timeFrame: 10 hours
measure: PYY3-36
timeFrame: 10 hours
measure: Breath Hydrogen
timeFrame: 10 hours
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05302869: Perceptions of Physiotherapy and Rehabilitation Professions
Official title: Perceptions of Physiotherapy and Rehabilitation Department Students and Graduated Physiotherapists About Their Professions
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Perception, Self
Physiotherapy
Keywords: Perception, Self
Physiotherapy
Lead sponsor: Acibadem University
Sponsor class: OTHER
First posted: 2022-03-31
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The current study will be conducted by face-to-face interviews within the scope of questionnaires prepared by us for students Students or a graduate physiotherapist

Brief summary: In this study, it is aimed to determine the perspectives and satisfaction of the students of the Physiotherapy and Rehabilitation Department about the physiotherapist profession, and to compare these results according to the class periods.

Our secondary aim is to determine the perspectives and satisfaction of graduate physiotherapists towards the physiotherapist profession and to compare these results according to their graduation years.


Eligibility criteria: Inclusion Criteria:

* Students in the physiotherapy and rehabilitation department or become a graduate physiotherapist

Exclusion Criteria:

* Students or a graduate physiotherapist with serious mental illness

Primary outcomes:
measure: Perceptions of students/physiotherapist about the physiotherapist profession
timeFrame: Baseline time
Secondary outcomes:
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Acibadem University
Study officials:
affiliation: Acibadem University
name: Nuray ALACA
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06435169: Comparative Presence of Piriformis Syndrome in Patients With Lumbar Disc Bulging and Protrusion
Official title: Comparative Presence of Piriformis Syndrome in Patients With Lumbar Disc Bulging and Protrusion
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Piriformis Syndrome
Lead sponsor: Yuzuncu Yıl University
Sponsor class: OTHER
First posted: 2024-05-30
Enrollment: 76
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients of both genders between the ages of 18-65 with lumbar disc bulging or protrusion

Brief summary: Clinicians consider lumbar disc herniation more prominently in the differential diagnosis than piriformis syndrome, as it is the most common cause of sciatica, and this canalizes them to overlook that the sciatic nerve may be compressed by the piriformis muscle, below the L4-L5-S1 intervertebral disc levels.

As far as is known, there are no 'patient series' in the literature regarding the incidence of Piriformis syndrome in Lumbar Disc Herniation, only one case report has been found. This clinical study aims to reveal that Piriformis syndrome may also be present in patients with disc herniation on Magnetic Resonance Imaging (MRI), and that sometimes it may even be the main cause of sciatic nerve pain.

Detailed description: In this study, the participants between the ages of 18-65, who were diagnosed with L4-L5 and/or L5-S1 Lumbar Disc Herniation (bulging and protrusion) by having a Lumbar MRI at the Faculty of Medicine Sports Medicine outpatient clinic, were reached through their contact numbers, and those who had not previously undergone waist/hip surgery and those who described unilateral sciatica complaints (hip-leg-foot pain and numbness) during the interview were invited to Yüzüncü Yıl University Faculty of Medicine Sports Medicine polyclinic and Lasegue's, Flexion Adduction Internal Rotation (FAIR) and Freiberg's tests were performed.

Eligibility criteria: Inclusion Criteria:

* Being between the ages of 18-65
* Having unilateral sciatica
* Having disk herniation in the form of bulging or protrusion in a previous Lumbar Magnetic Resonance Imaging (MRI)

Exclusion Criteria:

* Having bilateral sciatica
* Having disc herniation in the form of extrusion or sequestration in a previous Lumbar Magnetic Resonance Imaging (MRI)
* Previous back and/or hip surgery

Primary outcomes:
measure: Lasegue's Test
timeFrame: Baseline
measure: Freiberg's Test
timeFrame: Baseline
measure: FAIR (Flexion Adduction Internal Rotation) test
timeFrame: Baseline
Secondary outcomes:
Other outcomes:
Locations:
city: Van
country: Turkey
facility: Volkan Şah
Study officials:
References:
Clinical trial NCT06610669: The Prevalence of Hyper-Lp(a)-Emia in the PMMHRI-Lp(a) Registry
Official title: The Prevalence, Patients' Characteristics, and Hyper-Lp(a)-Emia Risk Factors in the Polish Population. The Polish Mother's Memorial Hospital Research Institute Lipoprotein(a) Registry
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Lipoprotein(a), Hyper-Lp(a)-Emia
Keywords: lipoprotein(a)
Lead sponsor: Polish Mother Memorial Hospital Research Institute
Sponsor class: OTHER
First posted: 2024-09-24
Enrollment: 2000
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: All consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases, Department of Endocrinology, and outpatient cardiology and endocrinology clinics with the measured Lp(a) concentration.

Brief summary: The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Department of Cardiology and Adult Congenital Heart Diseases, Department of Endocrinology, and outpatient cardiology and endocrinology clinics with the measured Lp(a) concentration have been included.

Detailed description: The PMMHRI-Lp(a)-Registry is a non-interventional, single-center registry conducted in Poland's 2nd largest, supra-regional hospital - the Polish Mother's Memorial Hospital Research Institute (PMMHRI). The PMMHRI-Lp(a)-Registry was established in January 2022. Since then, all consecutive patients of the Departments of Cardiology, Endocrinology, and outpatient cardiology and endocrinology clinics have been included. The indications for Lp(a) measurement in the registry are based on the 2021 Polish Lipid Guidelines and new Polish recommendations on the management of elevated Lp(a) (2024). Lp(a) was determined using Sentinel's Lp(a) Ultra, an Immunoturbidimetric quantitative test (Sentinel, Milan, Italy), and the results are presented in mg/dl.

The following information was collected from the patient's medical records: demographic parameters; relevant comorbidities; concomitant medications including lipid-lowering therapy status, anticoagulation status; smoking status; post hoc calculated cardiovascular risk score; and laboratory parameters including i.e. Lp(a) and lipids profile.

Eligibility criteria: Inclusion Criteria:

* measured lipoprotein(a) concentration

Exclusion Criteria:

-

Primary outcomes:
measure: Prevalence of hyper-Lp(a)-aemia among the Polish population, along with the identification of associated patient characteristics and risk factors
timeFrame: 5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Łódź
country: Poland
facility: Polish Mother Memorial Research Institute
Study officials:
References:
Clinical trial NCT01597869: Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study
Official title: Safety of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration : A Prospective Study
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Ultrasound
Complication
Lead sponsor: Samsung Medical Center
Sponsor class: OTHER
First posted: 2012-05-14
Enrollment: 300
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Patients admmitted to the tertiary hospital

Brief summary: The purpose of this study is to find all kinds of complications and it's frequency related to the Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) and to evaluate associated risk factors in patients who developed complications. The investigators performs EBUS-TBNA examination on all subjects that need mediastinal evaluation. All complications during or after the procedure will be recorded prospectively.


Eligibility criteria: Inclusion Criteria:

* Mediastinal lymph node enlargement on chest CT or PET-CT

Exclusion Criteria:

* Inadequate oxygenation during procedure
* uncontrolled cardiac arrythmia
* Bleeding diathesis
* Severe thrombocytopenia
* Recent use of clopidogrel
* Uncooperative patients

Primary outcomes:
measure: Complications related with EBUS-TBNA
timeFrame: 1 month interval
Secondary outcomes:
measure: Risk factors related with the development of complications
timeFrame: 1 month interval
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Samsung Medical Center
Study officials:
affiliation: Samsung Medical Center
name: Kyung Jong Lee, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01092169: Prevalence Of Microalbuminuria Among Children Suffering From Sickle Cell Nephropathy and Sickle Cell/Beta-Thalassemia
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Sickle Cell Anemia
Beta-Thalassemia
Microalbuminuria
Lead sponsor: Hillel Yaffe Medical Center
Sponsor class: OTHER_GOV
First posted: 2010-03-24
Sex: ALL
Maximum age (years): 25
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Young people suffering from SCA as well as those who suffer from combined sickle cell/beta-thalassemia, between 0-25 years old.

Brief summary: Sickle cell nephropathy is a known complication of sickle cell anemia (SCA) manifested by increase in glomerular filtration rate (glomerular hyperfiltration) and results in proteinuria and chronic renal failure.

Our goal is to examine the prevalence of proteinuria and microalbuminuria as an early predictive factor of glomerular injury, among young people who suffer from SCA as well as those who suffer from combined sickle cell/beta-thalassemia.


Eligibility criteria: Inclusion Criteria:

* Patients diagnosed with sickle cell anemia
* Patients diagnosed with combined sickle cell anemia/beta-thalassemia

Exclusion Criteria:

* Diabetes mellitus
* Hypertension
* Reduced renal mass (single kidney)
* Overweight
* History of UTIs

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT00215969: Prospective Study in Pregnant Women With Hypercoagulopathy
Official title: Prospective Study of Hypercoagulation in Pregnant Women
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Pre-Eclampsia
Eclampsia
Keywords: Pre-eclampsia
Pregnancy
Hypercoagulation
Screening
Cardiovascular complications
Lead sponsor: Hillerod Hospital, Denmark
Sponsor class: OTHER
Collaborators: name: Department of Clinical Trials, Denmark
name: Loyola University
First posted: 2005-09-22
Enrollment: 600
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE

Brief summary: Pre-eclampsia is one of the most common causes of maternal and fetal morbidity and mortality. The aim of this study is to identify pregnant women at risk for pre-eclampsia or other cardiovascular complications at a very early state of the disease, and thereby improve the current method of screening.

Detailed description: 600 pregnant women will be included in the project and followed in a standardized manner during their pregnancy. On a regular basis blood- and urine samples will be taken throughout their pregnancy and until 1 month after delivery and analyzed for a large variety of coagulation factors in order to identify factors that might predict an increased risk of developing pre-eclampsia and/or cardiovascular events. In addition a DNA-sample is taken if consented in order to evaluate genetic factors.

Eligibility criteria: Inclusion Criteria:

* Pregnant women attending the midwife at Hilleroed Hospital, Frederiksborg County, Denmark.

Exclusion Criteria:

* Mental disease.
* Problems understanding or reading Danish.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Hilleroed
country: Denmark
facility: Department of Gynaecology and Obstetrics, Hilleroed Hospital
state: Frederiksborg County
city: Hilleroed
country: Denmark
facility: Department of Gynaecology and Obstetrics
state: Frederiksborg
Study officials:
name: Anita S Andersen, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00693069: Effect of Different Dosing Regimens of Clopidogrel Before Elective Percutaneous Coronary Intervention (PCI) on Platelet Function
Official title: Effect of Different Dosing Regimens of Clopidogrel Given Before Elective Percutaneous Coronary Intervention on Platelet Function
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Coronary Artery Disease
Keywords: angioplasty
clopidogrel
coronary artery disease
platelets
Percutaneous coronary intervention
Lead sponsor: Hopital du Sacre-Coeur de Montreal
Sponsor class: OTHER
First posted: 2008-06-06
Enrollment: 120
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Adequate platelet inhibition before percutaneous coronary intervention (PCI) reduces peri-procedural and long-term ischemic complications. Documented reduced response to clopidogrel has been associated with subsequent major adverse cardiovascular events. Strategies to optimize platelet inhibition pre-PCI are under investigation.

This study sought to evaluate the effect on platelet aggregation of four different dosing regimens of clopidogrel given before elective PCI.


Eligibility criteria: Inclusion Criteria:

* Adult patient with an indication for elective coronary angiography with or without PCI

Exclusion Criteria:

* major hemorrhagic diathesis or active bleeding
* acute myocardial infarction (MI) within 14 days of enrolment
* unstable angina with ST-segment changes \>1 mm in at least two contiguous electrocardiographic leads at rest or a troponin I level \>0.06 microg/L within 14 days of enrolment
* stroke within the past 3 months
* platelet count \<100 x 10 9/L
* prothrombin time \> 1.5 times control
* hematocrit \<25% or hemoglobin level \<100 g/L
* alcohol or drug abuse
* enrolment in other investigational drug trials within the previous month
* use of thienopyridines, glycoprotein (GP) IIb/IIIa inhibitors, warfarin or acenocoumarol within the previous week
* allergic reaction or any contraindication to clopidogrel or aspirin administration

Primary outcomes:
measure: The primary objective of this study was to evaluate the effect of four different dosing regimens of clopidogrel on platelet aggregation at the time of diagnostic coronary angiography, and 2 hours after stenting.
timeFrame: 7 days
Secondary outcomes:
measure: A secondary objective in patients stented was the 30-day incidence of the composite of death, myocardial infarction (MI) or urgent target vessel revascularization.
timeFrame: 30 days
Other outcomes:
Locations:
city: Montreal
country: Canada
facility: Hopital du Sacre-Coeur de Montreal
state: Quebec
Study officials:
affiliation: Hopital du Sacre-Coeur de Montreal
name: Jean G Diodati, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01227369: Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment
Official title: Quality of Life(QoL) in Korean Postmenopausal Osteoporosis Patients With Bisphosphonate Treatment
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Osteoporosis, Postmenopausal
Keywords: Bisphosphonates
OPSAT-Q
Lead sponsor: GlaxoSmithKline
Sponsor class: INDUSTRY
First posted: 2010-10-25
Enrollment: 4376
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: PROBABILITY_SAMPLE
Study population: According to 2006 national health insurance data, a total of osteoporosis women (ICD-10 code: M81) are about 244,190 in Korea According to recent market research data, 95% of osteoporosis women use bisphosphonate in Korea.

With considering 95% market share of bisphosphonate in osteoporosis market, there are 231,714 Korean osteoporosis women. Applying for 2% extracting fraction in this study, total size of study population are 4,634.

Brief summary: Quality of Life (QoL) in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Detailed description: Cross-sectional quality of life survey using self-administered OPSAT-QTM questionnaire in Korean postmenopausal osteoporosis patients with bisphosphonate treatment

Eligibility criteria: Inclusion Criteria:

* Who have been diagnosed with postmenopausal osteoporosis by physician Who have received any oral bisphosphonates (weekly or monthly) at least for 2 months to provide answer of OPSAT-QTM questionnaire Who provide informed consent for study participation

Exclusion Criteria:

* Do not understand the contents of the questionnaire

Primary outcomes:
measure: Mean of composite satisfaction score (CSS) of OPSAT-QTM
timeFrame: 0day
Secondary outcomes:
measure: Mean of subscale satisfaction scores of OPSAT-QTM
timeFrame: oday
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: GSK Investigational Site
Study officials:
affiliation: GlaxoSmithKline
name: GSK Clinical Trials
role: STUDY_DIRECTOR
References: